Selenopeptide Nanomedicine Activates Natural Killer Cells for Enhanced Tumor Chemoimmunotherapy

Bibliographische Detailangaben
Veröffentlicht in:	Advanced materials (Deerfield Beach, Fla.). - 1998. - 34(2022), 17 vom: 01. Apr., Seite e2108167
1. Verfasser:	Wei, Ziyu (VerfasserIn)
Weitere Verfasser:	Yi, Yu, Luo, Zhen, Gong, Xiaoyun, Jiang, Yuxing, Hou, Dayong, Zhang, Li, Liu, Zimo, Wang, Mandi, Wang, Jie, Guo, Ruochen, Yang, Jinjun, Wang, Lei, Wang, Hao, Zhao, Yuliang
Format:	Online-Aufsatz
Sprache:	English
Veröffentlicht:	2022
Zugriff auf das übergeordnete Werk:	Advanced materials (Deerfield Beach, Fla.)
Schlagworte:	Journal Article chemoimmunotherapy drug delivery programmable nanomedicine selenopeptide self-assembly Doxorubicin 80168379AG

Beschreibung
Zusammenfassung:	© 2022 Wiley-VCH GmbH. Chemoimmunotherapy using nanotechnology has shown great potential for cancer therapy in the clinic. However, uncontrolled transportation and synergistic responses remain challenges. Here, a self-assembled selenopeptide nanoparticle that strengthens tumor chemoimmunotherapy through the activation of natural killer (NK) cells by the oxidative metabolite of the selenopeptide is developed. With the advantages of the enzyme-induced size-reduction and the reactive-oxygen-species-driven deselenization, this selenopeptide is able to deliver therapeutics, e.g., doxorubicin (DOX), to solid tumors and further activate the NK cells in a programmed manner. Importantly, in vitro and in vivo results prove the mutual promotion between the DOX-induced chemotherapy and the selenopeptide-induced immunotherapy, which synergistically contribute to the improved antitumor efficacy. It is anticipated that the selenopeptide may provide a type of promising stimuli-responsive immune modulator for versatile biomedical applications
Beschreibung:	Date Completed 28.04.2022 Date Revised 28.04.2022 published: Print-Electronic Citation Status MEDLINE
ISSN:	1521-4095
DOI:	10.1002/adma.202108167